Week | Treatment | Weight | FBG | HbA1c | n |
---|---|---|---|---|---|
g | mg/dl | % (mol/mol)a | |||
10 | Veh + Veh | 34.1 ± 2.5 | 127 ± 12 | — | 4 |
STZ + Veh | 27.3 ± 1.1 | 540 ± 96* | — | 4 | |
12 | Veh + Veh | 34.0 ± 1.7 | 122 ± 10 | 5.0 ± 0.4 (31 ± 4.4) | 6 |
STZ+ Veh | 30.3 ± 3.9 | 600* | 12.9 ± 0.2* (117 ± 2.2) | 7 | |
16 | Veh + Veh | 43.0 ± 3.1 | 117 ± 6 | 5.4 ± 0.7 (36 ± 7.7) | 4 |
STZ + Veh | 28.6 ± 4.1 | 573 ± 54* | 11.7 ± 0.9* (104 ± 9.8) | 4 | |
18 | Veh + Veh | 43.8 ± 3.1 | 114 ± 15 | 4.7 ± 0.2 (28 ± 2.2) | 4 |
STZ + Veh | 29.3 ± 4.2 | 564 ± 35* | 9.9 ± 1.8* (85 ± 19.7) | 4 | |
Veh + KU-32 | 39.2 ± 2.2 | 138 ± 18 | 4.6 ± 0.3 (27 ± 3.3) | 4 | |
STZ + KU-32 | 30.8 ± 1.7 | 589 ± 21* | 10.7 ± 0.8 * (93 ± 8.7) | 4 | |
20 | Veh + Veh | 40.2 ± 3.9 | 125 ± 9 | 4.9 ± 0.2 (30 ± 2.2) | 4 |
STZ + Veh | 32.7 ± 2.8 | 600* | 12.1 ± 0.6* (109 ± 6.6) | 4 | |
Veh + KU-32 | 41.4 ± 2.6 | 120 ± 1 | 5.2 ± 0.6 (33 ± 6.6) | 4 | |
STZ + KU-32 | 33.0 ± 6.0 | 600* | 12.1 ± 0.9* (109 ± 9.8) | 3 | |
22 | Veh + Veh | 44.0 ± 0.6 | 123 ± 10 | 5.1 ± 0.1 (32 ± 1.1) | 4 |
STZ + Veh | 30.3 ± 2.6 | 600* | 10.2 ± 1.7 * (88 ± 18.6) | 3 | |
Veh + KU-32 | 43.0 ± 2.6 | 120 ± 1 | 4.8 ± 0.3 (29 ± 3.3) | 4 | |
STZ + KU-32 | 35.9 ± 0.9 | 600* | 10.7 ± 1.6 * (93 ± 17.5) | 3 |